HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis.

Abstract
A new double-strength (84 micrograms/spray) formulation of beclomethasone dipropionate (BDP-ds) as an aqueous suspension has been introduced to control symptoms of allergic rhinitis with once-daily intranasal dosing. This paper reviews the results of three clinical reports which show that BDP-ds given once a day is more effective than placebo and as effective as regular-strength beclomethasone dipropionate given twice daily in reducing the nasal symptoms of seasonal allergic rhinitis. Symptom improvement was seen within 2 days of treatment initiation and was maintained for the subsequent 4 weeks. BDP-ds was found to be as safe and well tolerated as placebo. Adverse effects, which were generally mild, included headache, nasal burning/irritation, epistaxis, coughing, and pharyngitis. BDP-ds is safe for children as young as 6 years of age, and its once-daily dosing schedule may improve patient compliance.
AuthorsP Chervinsky
JournalClinical therapeutics (Clin Ther) 1996 Sep-Oct Vol. 18 Issue 5 Pg. 790-6; discussion 789 ISSN: 0149-2918 [Print] United States
PMID8930423 (Publication Type: Journal Article, Review)
Chemical References
  • Glucocorticoids
  • Beclomethasone
Topics
  • Administration, Intranasal
  • Adult
  • Beclomethasone (administration & dosage, therapeutic use)
  • Child
  • Drug Tolerance
  • Glucocorticoids (administration & dosage, therapeutic use)
  • Humans
  • Rhinitis, Allergic, Seasonal (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: